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INTRODUCTION 
Cardiovascular diseases (CVD) are the major cause of 
death globally. Dyslipidaemia is one of the major risk 
factor for the CVD, along with other factors such as 
hypertension, smoking, obesity etc. Dyslipidaemias are 
primary disorders of lipoprotein metabolism (due to 
genetic reason) or secondary disorders induced by other 
metabolic causes such as diabetes mellitus, 
hypothyroidism or hypopituitarism. Dyslipidaemias are a 
common clinical problem which includes either lipoprotein 
overproduction or its deficiencies. Mixed dyslipidaemia is 
characterised by elevated levels of triglycerides (TG) and 
reduced High Density Lipoprotein cholesterols (HDL-C), 
with or without elevated levels of low density lipoprotein 
cholesterol (LDL-C). These metabolic abnormalities 
contribute to increased risk for CVD. Lipoproteins are 
spherical particles of water soluble proteins, which 
transport TGs, cholesterols (CH) and cholesterol esters 
(CE) through body fluids. A metabolic disorder of 
lipoproteins causing elevation in any kind of lipoproteins 
is called hyperlipidaemias or hyperlipoproteinemias. Itis a 
major cause of acute pancreatitis and atherosclerosis.3 The 
first is more prevalent in patients with hyperlipaemia, 
which is characterised sby very high level of TG. The term 
‘dyslipidaemia’ is nowadays preferred over 
hyperlipidaemia or hyperlipoproteinemia. Lipoproteins act 
synergistically with various environmental and metabolic 
factors to promote atherosclerosis and thrombosis. They 
are smoking, diabetes mellitus, obesity, and high blood 
pressure. Anunderlying relationship between serum 
lipoprotein concentration and atherosclerosis is evidenced 
by various epidemiologic, pathologic, animal, genetic and 
metabolic studies.4 Hyperlipidaemia is also major cause of 
atherosclerosis-associated conditions such as coronary 
heart disease, ischemic cerebrovascular disease, and 
peripheral vascular disease. Atherosclerosis and 
atherosclerosis -associated conditions are leading cause of 
death globally and in particular western countries. 
Lipoproteins that contain apo-lipoprotein B 100 such as 
LDL, VLDL, lipoprotein-a transport lipids into the artery 
wall, causing slow occlusion of coronary vessels and 
thereby leading to formation of thrombi. On the other 
hand, HDLretrieve cholesterol from the artery wall and 
inhibit oxidation of atherogenic lipoproteins. Thereby 
HDL exerts antiatherogenic effect. Therefore it can be 
stated that low level of HDL (in case of cigarette smoking) 
and oxidative stress (in case if diabetes mellitus)are risk 
factor for atherosclerotic diseases.Measurement of plasma 
apo-lipoprotein B 100 concentration and non HDL-C 
become important parameter for understanding 
dyslipidaemia. Effective treatment of dyslipidaemias either 
by pharmacological or non-pharmacological interventions 
has shown reduced cardiovascular disease morbidity and 
mortality in many trials.5-7Although LDL-C is the main 
culprit for the lipoprotein associated risk, but LDL-C level 
does not reflect the classic diabetic dyslipidaemias. HIV 
infection as well as its treatment is linked with 
abnormalities in lipid metabolism. Patients with HIV 
associated fat redistribution are more likely to have 
dyslipidaemia, possibly related to excess visceral adipose 
tissue accumulation.8 
DYSLIPIDAEMIA CLASSIFICATION 
Dyslipidaemia is classified into four categories (as listed in 
table below) based on clinical, genetic and biochemical 
parameters. Each of these four categories has a specific 
therapeutic approach.  
1. Elevated LDL-C: Elevation of LDL-C, without an 
elevation of TG is considered as primary or familial 
hypercholesterolemia (FH). It occurs due to defects in 
LDL receptor gene. This affects approximately 1 in 500 
Americans, and 1 in 200 French Canadians.  
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2. Very high TG: Fasting TG level over 1000 mg/dl 
can be due to genetic influences, or a combination of 
genetic predisposition and secondary causes such as 
alcohol abuse, poorly controlled diabetes, obesity, renal 
disease etc.9 They have relatively low risk of CHD, but 
have a high risk of pancreatitis, mostly due to lipemia and 
subsequent hyper viscosity.
10
 
3. Low HDL-C: HDL-cholesterol is a most 
prevailing predictor of premature CHD along with 
thrombotic risk factors among young Indians and 
Americans.11,12 Low HDL-C is associated with genetic 
factors, male sex, hypertriglyceridemia, smoking, obesity. 
Familial hypoalphalipoproteinemia is prevalent in 
approximately 10 per cent of CHD patients aged below 60 
years. Within families affected by early and apparently 
genetic CHD, dyslipidaemias have a much higher 
occurrence than that in the general population. A  20%-
30% of early familial CHD has been attributed to primary 
hypoalphalipoproteinemia (low HDL-C).13 
4. Combined dyslipidaemias: It is most prevalent in 
patients who survive myocardial infarction or suffering 
from coronary revascularization. It includes abnormalities 
of several lipoproteins, mainly elevated LDL-C and TG 
with low HDL-C. This disorder does not become apparent 
until adulthood. 
 
Table 1:  Classification of dyslipidaemias 
Lipoprotein levels (mg/dl) Fredrickson-Levy class Genetic disorder 
LDL-C
*
 elevated 
LDL-C > 130 
TG**< 150 
HDL-C***>40 
II A Familial hypercholesterolemia (LDL>200) 
Primary hypercholesterolemia (LDL 130-199) 
TG elevated 
TG>500 
LDL-C NA**** 
HDL-C NA 
I, V LPL deficiency 
Apo C-III deficiency 
Familial hypertriglyceridemia 
HDL-C decreased 
HDL-C < 40 
TG < 150 
LDL-C < 130 
- Hypo-α-lipoproteinemia 
Combined dyslipidaemias 
LDL-C > 130 
TG > 150 
HDL-C < 40 
II B, IV, III Familial combined hyperlipidemia 
Familial dysbetalipoproteinemia 
 
*LDL-C=Low density lipoprotein- Cholesterol, **TG=Triglycerides, ***HDL-C=High density lipoprotein-Cholesterol, ****NA=Not applicable. 
 
SCREENING GUIDELINES FOR DETECTION OF 
DYSLIPIDAEMIAS 
As per American Association of Clinical Endocrinologists 
(AACE) Clinical Practice Guideline, screening for 
detection of dyslipidaemia can be done through several 
stages. First and foremost steps are identifying the risk 
factors and categorize them. This will maximize the 
treatment effectiveness. Major risk factors include 
advancing age, high serum total cholesterol level, high non 
HDL –C level, established coronary artery diseases 
(CAD), family history of CAD, presence of hypertension, 
diabetes mellitus, cigarette smoking. Additional risk 
factors include obesity, elevated apo B, polycystic ovary 
syndrome in women etc. It is important to determine the 10 
year risk of a coronary event using various tools such as 
Framingham Risk assessment Tool or by Reynolds Risk 
score.(14)AACEClinical Practice Guideline recommends 
that special attention to be given for assessing women for 
CAD risk. AACE screening recommendations are based 
on age and risk, not based on sex, therefore, women should 
be screened in the same way as men. As per AACE 
recommendation, early diagnosis and management of 
paediatric dyslipidaemia to reduce the levels of LDL-C 
that may eventually increase risk of cardiovascular events 
in adulthood need to be carried out. AACE also 
recommends more frequent assessments for all patients 
with a family history of premature CAD (myocardial 
infarction or sudden death before 55 years of age in father 
or other male first-degree relative, or before 65 years of 
age in mother or other female first-degree relative). Adult 
patients with diabetes mellitus should be screened annually 
for dyslipidaemia. All adults of 20 years of age should be 
evaluated every 5 years as part of a global risk assessment 
for dyslipidaemia. In the absence of CAD risk factors, 
middle-aged persons (Men Aged 45-65 Years, Women 
Aged 55-65 Years) should be screened for dyslipidaemia 
at least every 1 to 2 years. Adults older than 65 years of 
age should undergo lipid assessment if they have multiple 
CAD risk factors.  AACE also recommends that children 
older than 2 years of age should be screened every 3 to 5 
years if they have CAD risk factors or having a family 
history of premature CAD or dyslipidaemia, or have 
insulin resistance syndrome, or have no available family 
history.  
SCREENING TESTS RECOMMENDATION 
Various screening tests are recommended by AACE for 
the detection of cardiovascular risks.
(14)
 
1. Fasting lipid profile: This includes total 
cholesterol, LDL-C, triglycerides, and HDL-C.  
2. Low-Density Lipoprotein Cholesterol 
measurement:  AACE recommends direct measurement of 
LDL-C in certain high-risk patients, such as those with 
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fasting TG levels greater than 250 mg/dl or those with 
diabetes mellitus or known vascular disease. 
3. High-Density Lipoprotein Cholesterol 
measurement: AACE recommends this test as a screening 
test for dyslipidaemia. An HDL-C concentration greater 
than 60 mg/dl is an independent negative risk factor in 
both sexes. 
4. Non High-Density Lipoprotein Cholesterol 
measurement: If insulin resistance is suspected, AACE 
recommends evaluation of non–HDL-C to know about 
patient’s total atherogenic lipoprotein burden. In addition, 
when TGs are 200 mg/dl or greater but less than 500 
mg/dl, a non HDL-C calculation will provide better risk 
assessment than LDL-C alone.  
5. Triglyceride estimation: AACE recommends 
screening of TGs as a component of lipid screening as 
elevated TG level is an important risk factor for CAD.  
6. Apolipoprotein estimation: AACE recommends 
Apo B measurements to assess the success of LDL-C 
lowering therapy.  
AACE TREATMENT RECOMMENDATIONS 
Goal is to attempt for lipid levels in the range of normal; 
however, more aggressive goals can be set for higher-risk 
patients. AACE recommends a broad strategy to control 
lipid levels and associated metabolic abnormalities and 
also to limit risk factors such as hypertension, diabetes, 
obesity, and cigarette smoking.Most cost effective 
treatment approach to dyslipidaemias and CAD is 
nonpharmacological interventions. Although 
pharmacotherapy is recommended for those patients who 
are at highest risk and fail to reach desiredcholesterol level 
after an adequate trial of lifestyle changes in 6 months.  
Pharmacotherapy: 
Currently available lipid lowering drugs include HMG-
CoA reductase inhibitors (statins), fibric acid derivatives 
(fibrates), nicotinic acid (niacin), bile acid sequestrates, 
and cholesterol absorption inhibitors (ezetimibe).  For 
isolated LDL-C elevations or elevated LDL-C after TG is 
controlled with combined dyslipidaemias, statins are the 
first drug of choice, although bile acid resins, psyllium 
have proven efficacy with gastrointestinal side effects. A 
number of intervention trials have shown that among 
statins, atorvastatin is most cost-effective for moderate to 
high risk patients.15 After treating secondary causes for TG 
> 400-500 mg/dl, niacin and gemfibrozil is the drug of 
choice. Fibrates are the choice of drug for 
hypertriglyceridemia associated with diabetes, gout etc. 
While TGs are being reduced with gemfibrozil, there is 
associated increase in LDL-C level. This can be treated 
with another fibrate group of drug fenofibrate. Omega 3 
fish oil capsule also lower TGs effectively, although can 
cause abdominal bloating, flatulence, diarrhoea. Mixed 
dyslipidaemia is frequently associated with glucose 
intolerance for which niacin is not effective. Otherwise 
statin, combining fibrate and psyllium are effective 
treatment approach. On the other hand isolated low HDL-
C are slow to response to treatment and for which only low 
to moderate dose niacin is the drug of choice. Patients on 
medications should be monitored every 4 to 6 weeks to 
adjust dose and evaluate side effects until lipid goals are 
achieved.  
Nonpharmacological interventions:  
This includes nutrition and regular exercise, weight 
management, and cessation of smoking.   
Exercise:  
Exercise remains an essential approach for dyslipidaemia 
control and cardiovascular risk factor reduction, as 
evidenced by various published guidelines. Physical 
activity is associated with improvement in lipoprotein 
profile. Daily physical activity increases the clearance of 
TG-rich lipoproteins and glucose. Exercise of moderate 
intensity, longer duration and increased frequency appears 
to have more benefit for dyslipidaemia and weight loss 
than higher intensity, less frequent activity. AACE 
recommends at least 30 minutes of moderate intensity 
physical activity (consuming 4-7 kcal/min) 4 to 6 times 
weekly, with an expenditure of at least 200 kcal/ day. 
Physical activities include brisk walking, aerobics, 
cleaning/scrubbing; mowing the lawn and various sporting 
activities such as basketball, or volleyball with light effort. 
Recent guidelines indicate that greater benefits are 
achieved when the duration of exercise is lengthened to 60 
to 90 minutes daily.16 ross-sectional evidence indicates that 
there is association between dyslipidaemia and reduced 
metabolic clearance of insulin (MCRI).17 Regular physical 
activity such as weight and resistance training also 
improves insulin sensitivity.  
Nutrition and weight management: 
Proper nutrition therapy provides an important instrument 
for the management of dyslipidaemia. The U.S. dietary 
guidelines and the food pyramid recommend choice of 
food that will reduce the risk of CVD in general 
population, and form basis for guidelines to treat 
dyslipidaemias.18 Dietary fat comprises both saturated as 
well as unsaturated fatty acids. The substitution of 
unsaturated fatty acids with saturated fatty acids leads to 
decreased LDL-C levels. High intake of poly unsaturated 
fatty acids reducesthe HDL-C and triglyceride levels. 
Substitution of monounsaturated fatty acids for saturated 
fatty acids has a minimal effect on HDL-C values and does 
not raise triglyceride levels. Whereas dietary intake of 
trans-fatty acids is associated with both increased LDL-C 
and decreased HDL-C levels. Current nutritional 
guidelines for the reduction of cardiovascular risk through 
lipid management recommend diets rich in fruits, 
vegetables, grains, legumes, high fibre cereals, low-fat 
dairy products, fish, lean meats, and skinless poultry. 
Guidelines also indicate that poly unsaturated and 
monounsaturated fatty acids may comprise up to 10% and 
20% of caloric intake, respectively, and that total dietary 
fat should constitute 25% to 35% of calories consumed. 
Diet recommendation for dyslipidaemia should be 
individualised based on patient’s lipid pattern, body 
weight, food preference, level of motivation. Patients with 
hypercholesterolemia are less responsive to diet changes 
than those with other forms of hypercholesterolemia.  
Including 20 to 30 g of dietary fibre per day, of which 10 
to 25 g is soluble, could result in an additional 5% to 15% 
reduction in TChol and LDL-C. Patients with combined 
dyslipidaemia and metabolic syndrome should control 
their weight in an proper manner and do regular exercise, 
as these changes will have a favourable impact on all 
serum lipoproteins, glucose intolerance and abnormal 
obesity. A 10% reduction in body weight is associated 
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with up to a 30% reduction in abnormal obesity. A patient 
should achieve this by limiting total fat intake to 25% to 
30% of calories and saturated fat to less than 7% of 
calories. Total carbohydrate intake should not exceed 60% 
of calories.  
Smoking cessation: 
Cigarette smoking is associated with a number of 
metabolic processes that affect lipoproteins, including 
increasing plasma free fatty acids, glucose and VLDL-C, 
and lowering HDL-C. Smoking cessation is associated 
with an average increase in HDL-C of 6 to 8 mg/dl.19 
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